Jupiter Asset Management’s Atea Pharmaceuticals AVIR Stock Holding History

Jupiter Asset Management’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-263,056	Closed	-$1.26M	–	417
2022 Q4	$1.26M	Hold	263,056	–	–	0.02%	356
2022 Q3	$1.5M	Hold	263,056	–	–	0.02%	366
2022 Q2	$1.86M	Sell	263,056 -7,484	-3%	-$51.1K	0.03%	382
2022 Q1	$1.95M	Buy	270,540 +122,943	+83%	+$835K	0.02%	354
2021 Q4	$1.33M	Buy	147,597 +124,753	+546%	+$1.94M	0.01%	399
2021 Q3	$801K	Buy	+22,844	New	+$634K	0.01%	436

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jupiter Asset Management's AVIR Position: Q1 2023 in Review

Jupiter Asset Management sold out of Atea Pharmaceuticals (AVIR) in Q1 2023, closing a stake of 263,056 shares — an estimated $1.26M sold.

Jupiter Asset Management first reported a position in AVIR in Q3 2021 and held it in 6 quarters. The position peaked at $1.95M in Q1 2022. 130 funds tracked by Wall St. Rank hold AVIR as of Q1 2023.

Jupiter Asset Management reported no remaining Atea Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Jupiter Asset Management sold 263,056 Atea Pharmaceuticals shares in Q1 2023, an estimated $1.26M.
Jupiter Asset Management first reported a position in Atea Pharmaceuticals in Q3 2021 and held it in 6 quarters.
Jupiter Asset Management's Atea Pharmaceuticals position peaked at $1.95M in Q1 2022.
130 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2023.

Based on Jupiter Asset Management's 13F filing for Q1 2023, filed 10 May 2023.